Lupus and the Antiphospholipid Syndrome in Pregnancy and Obstetrics: Clinical Characteristics, Diagnosis, Pathogenesis, and Treatment

ABSTRACT

The antiphospholipid syndrome (APS) in pregnancy is associated with repeated miscarriages and fetal loss. Other complications of pregnancy such as preeclampsia and placental insufficiency are also frequently reported during pregnancy in APS. The pathogenesis of pregnancy failures in APS is related to both the thrombophilic effect of antiphospholipid antibodies and also to different mechanisms including a direct effect of antibodies on trophoblast differentiation and invasion. Although optimal pharmacologic treatment is essential to achieve a successful outcome in APS pregnancy, the standard APS pharmacologic treatment alone may not be sufficient. A good obstetric outcome is the result of careful obstetric monitoring, proper delivery timing, and skillful neonatal care. A multidisciplinary team (obstetricians, rheumatologists, and neonatologists) and the progress in neonatal intensive care are as important as drugs in achieving a good obstetric outcome and to reduce the possible consequences of premature delivery.

KEYWORDS

Antiphospholipid antibodies - antiphospholipid syndrome - recurrent miscarriages - fetal loss - preeclampsia - HELLP syndrome

REFERENCES

• 1 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 2 Alarcon-Segovia D, Deleze M, Oria C V et al.. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.  Medicine (Baltimore). 1989;  68 353-365
• 3 Alarcon-Segovia D, Deleze M, Oria C V et al.. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.  Medicine (Baltimore). 1989;  68 353-365
• 4 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 752-763
• 5 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification for definite antiphospholipid syndrome.  Arthritis Rheum. 1999;  42 1309-1311
• 6 Maier D B, Parke A. Subclinical autoimmunity in recurrent aborters.  Fertil Steril. 1989;  51 280-285
• 7 Stephenson M D. Frequency of factors associated with habitual abortion in 197 couples.  Fertil Steril. 1996;  66 24-29
• 8 Oshiro B T, Silver R M, Scott J R, Yu H, Branch D W. Antiphospholipid antibodies and fetal death.  Obstet Gynecol. 1996;  87 489-493
• 9 Lima F, Khamashta M A, Buchanan N M, Kerslake S, Hunt B J, Hughes G R. A study of sixty pregnancies in patients with the antiphospholipid syndrome.  Clin Exp Rheumatol. 1996;  14 131-136
• 10 Branch D W, Dudley D J, Scott J R, Silver R M. Antiphospholipid antibodies and fetal loss.  N Engl J Med. 1992;  326 952-954
• 11 Branch D W, Andres R, Digre K B et al.. The association of antiphospholipid antibodies with severe preeclampsia.  Obstet Gynecol. 1989;  73 541-545
• 12 Faden D, Tincani A, Tanzi P et al.. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia.  Eur J Obstet Gynecol Reprod Biol. 1997;  73 37-42
• 13 Clark E A, Silver R M, Branch D W. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?.  Curr Rheumatol Rep. 2007;  9 219-225
• 14 Asherson R A, Galarza-Maldonado C, Sanin-Blair J. The HELLP syndrome, antiphospholipid antibodies, and syndromes.  Clin Rheumatol. 2008;  27 1-4
• 15 Le Thi Thuong D, Tieulié N, Costedoat N et al.. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women.  Ann Rheum Dis. 2005;  64 273-278
• 16 Tsirigotis P, Mantzios G, Pappa V et al.. Antiphospholipid syndrome: a predisposing factor for early onset HELLP syndrome.  Rheumatol Int. 2007;  28(2) 171-174
• 17 Erkan D, Tincani A, Meroni P, Lockshin M. Practice questions/answers about antiphospholipid syndrome pregnancy. Presented at: the American College of Rheumatology annual meeting November 6–11, 2007 Boston, MA;
• 18 Carp H J, Shoenfeld Y. Anti-phospholipid antibodies and infertility.  Clin Rev Allergy Immunol. 2007;  32 159-161
• 19 Sanmarco M, Bardin N, Camoin L et al.. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization.  Ann N Y Acad Sci. 2007;  1108 457-465
• 20 Long A A, Ginsberg J S, Brill-Edwards P et al.. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study.  Thromb Haemost. 1991;  66 520-524
• 21 Petri M. Classification and epidemiology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Amsterdam; Elsevier 2002: 11-20
• 22 Cervera R, Piette J C, Font J et al.. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 1019-1027
• 23 Blank M, Krause I, Fridkin M et al.. Bacterial induction of autoantibodies to b2 glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.  J Clin Invest. 2002;  109 797-804
• 24 Goel N, Ortel T, Bali D et al.. Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance.  Arthritis Rheum. 1999;  42 318-327
• 25 Savi M, Ferraccioli G F, Neri T M et al.. HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients.  Arthritis Rheum. 1988;  31 1568-1570
• 26 Arnett F C, Thiagarajan P, Ahn C, Reveille J D. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups.  Arthritis Rheum. 1999;  42 268-274
• 27 Caliz R, Atsumi T, Kondeatis E et al.. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients.  Rheumatology. 2001;  40 31-36
• 28 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiohospholipid syndrome in naïve mice with lupus monoclonal and human polyclonal anticardiolipin antibodies.  Proc Natl Acad Sci U S A. 1991;  88 3069-3073
• 29 Meroni P L, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome.  Curr Opin Rheumatol. 2001;  13 377-382
• 30 Rote N S, Lyden T W, Vogt E et al.. Expression of phosphatidylserine epitopes during trophoblast membrane fusion: an alternative hypothesis for antiphospholipid antibody associated pregnancy disorders. In: Dondero E, Johnson PM Reproductive Immunology. New York; Serono Symposia Publications, Raven Press 1993 97: 281-284
• 31 Rand J H. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome.  J Autoimmun. 2000;  15 107-111
• 32 Di Simone N, Raschi E, Testoni C et al.. Pathogenic role of anti-β₂-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of β₂-glycoprotein I binding to trophoblast cells and functional effects of anti-β₂-glycoprotein I antibodies in vitro.  Ann Rheum Dis. 2005;  64 462-467
• 33 Holers V M, Girardi G, Mo L et al.. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.  J Exp Med. 2002;  195 211-220
• 34 Girardi G, Berman J, Redecha P et al.. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.  J Clin Invest. 2003;  112 1644-1654
• 35 Martinez de la Torre Y, Buracchi C, Borroni E M et al.. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6.  Proc Natl Acad Sci U S A. 2007;  104 2319-2324
• 36 Meroni P L, Di Simone N, Testoni C et al.. Antiphospholipid antibodies as cause of pregnancy loss.  Lupus. 2004;  13 649-652
• 37 Venkat-Raman N, Backos M, Teoh T G et al.. Uterine artery Doppler in predicting pregnancy outcome in women with antiphospholipid syndrome.  Obstet Gynecol. 2001;  98 235-242
• 38 Sangle S, D'Cruz D P, Hughes G R. Livedo reticularis and pregnancy morbidity in patients negative for antiphospholipid antibodies.  Ann Rheum Dis. 2005;  64 147-148
• 39 Lockshin M D, Sammaritano L R, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome.  Arthritis Rheum. 2000;  43 440-443
• 40 Blank M, Shoenfeld Y. Antiphosphatidylserine antibodies and reproductive failure.  Lupus. 2004;  13 661-665
• 41 Shoenfeld Y, Carp H J, Molina V et al.. Autoantibodies and prediction of reproductive failure.  Am J Reprod Immunol. 2006;  56 337-344
• 42 Lubbe W F, Butler W S, Palmer S J et al.. Fetal survival after prednisone suppression of maternal lupus-anticoagulant.  Lancet. 1983;  1 1361-1363
• 43 Coomarasamy A, Honest H, Papaioannou S et al.. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review.  Obstet Gynecol. 2003;  101 1319-1332
• 44 Cowchock F S, Reece E A, Balaban D et al.. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.  Am J Obstet Gynecol. 1992;  166 1318-1323
• 45 Rai R, Cohen H, Dave M et al.. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipids antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
• 46 Kutteh W H. Antiphospholipid antibody associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
• 47 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized controlled trial of treatment.  Obstet Gynecol. 2002;  100 408-413
• 48 Khamashta M A, Cuadrado M J, Mujic F et al.. The management of thrombosis in the antiphospholipid antibody syndrome.  N Engl J Med. 1995;  332 993-997
• 49 Tincani A, Branch W, Levy R A et al.. Treatment of pregnant patients with antiphospholipid syndrome.  Lupus. 2003;  12 524-529
• 50 Pauzner R, Dulitzki M, Lanevitz P et al.. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.  Thromb Haemost. 2001;  86 1379-1384
• 51 Ostensen M, Khamashta M, Lockshin M et al.. Anti-inflammatory and immunosuppressive drugs and reproduction. Available at: http://arthritis-research.com/content/8/3/209 Accessed July 16, 2008
• 52 Ruiz-Irastorza G, Khamashta M A, Hughes G R. Heparin and osteoporosis during pregnancy: 2002 update.  Lupus. 2002;  11 680-682
• 53 Branch D W, Peaceman A M, Druzin M et al.. A multicenter, placebo controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.  Am J Obstet Gynecol. 2000;  182 122-127
• 54 Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.  Lupus. 1996;  5 S16-S22
• 55 Sammaritano L R. Therapy insight: guidelines for selection of contraception in woman with rheumatic disease.  Nat Clin Pract Rheumatol. 2007;  3 273-281
• 56 Zatti S, Biasini Rebaioli C, Lojacono A. Antiphospholipid syndrome and pregnancy.  Women's Health. 2006;  2 873-880